Description
Release form
Solution for intravenous and intramuscular administration.
Packing
10 ampoules of 4 ml.
Pharmacological action
The pharmacological effect is due to anti-ischemic, antioxidant, membrane-stabilizing and immunomodulating properties.
Prevents the death of hepatocytes, reduces the degree of their fatty infiltration and the spread of centrolobular liver necrosis, promotes the regeneration of hepatocytes, normalizes protein, carbohydrate, lipid and pigment exchanges.
Increases the amount of synthesis and secretion of bile, normalizes its chemical composition.
Thiotriazolin ® enhances the compensatory activation of anaerobic glycolysis, reduces the inhibition of oxidation processes in the Krebs cycle while maintaining the intracellular fund of ATP.
The drug activates the antioxidant system and inhibits the processes of lipid oxidation in ischemic areas. Improves the rheological properties of blood (activates the fibrinolytic system).
Indications
Toxic lesions of the liver, including alcohol, viral and medicinal origin (antibiotics, antitumor, antituberculosis, antiviral drugs, tricyclic antidepressants, oral contraceptives, etc.).
Chronic alcoholic hepatitis with minimal to moderate activity.
Chronic viral hepatitis, fatty liver, cirrhosis.
Contraindications
Hypersensitivity to the components of the drug.
Renal failure.
Children’s age.
Pregnancy and lactation.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
None.
Composition
In 1 ml of solution contains:
Active ingredient:
morpholinium-methyl-triazolyl-thioacetate (thiotriazolin®) 25 mg in terms of 100% of the substance.
Excipients:
water for injection up to 1 ml.
Dosage and administration of
In chronic hepatitis, Thiotriazolin ® is administered intramuscularly in a dose of 2 ml of a 2.5% solution 2-3 times a day (2-3 times 50 mg), or slowly intravenously at a rate of 2 ml / min at the same time 4 ml of 2.5% solution (100 mg), or drip at a speed of 20-30 drops per minute (2 ampoules of 2.5% solution are dissolved in 150 – 250 ml of physiological saline).
From the fifth to the twentieth day of treatment, Thiotriazolin ® is prescribed in tablets (100 mg 3 times a day).
The course of treatment is 20-30 days.
Side effects
Thiotriazolin ® is generally well tolerated. With the clinical use of Thiotriazolin ®, the following adverse reactions are extremely rare:
From the gastrointestinal tract: nausea, dry mouth, bloating.
From the central and peripheral nervous system: general weakness, dizziness, tinnitus.
From the cardiovascular system: tachycardia, increased blood pressure, pain in the heart, arrhythmias.
From the respiratory system: very rarely – shortness of breath, asthma attacks. allergic reactions: hypersensitivity reactions, fever, very rarely – Quincke edema.
From the skin: itching, flushing of the skin, urticaria local reactions: in rare cases, a tingling sensation and redness at the injection site.
Overdose
Cases of overdose unknown.
Storage conditions
Store in a dark place at a temperature of 15 ° C to 25 ° C.
Keep out of the reach and sight of children.
Expiration
4 years.
active substance
morpholin-Methyl-triazol-thioacetate
Prescription conditions
pharmacy Prescription
Dosage form
solution for injection and infusions
Halychpharm, Ukraine
